Brentuximab vedotin: Delivering an antimitotic drug to activated lymphoma cells

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Importance of the field: Patients with relapsed or refractory CD30-positive lymphoproliferative disorders such as Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) commonly have a poor prognosis. Patients with these histologies who subsequently progress after salvage chemotherapy and autologous stem cell transplantation (ASCT) have very limited treatment options and are in need of novel effective therapies. Areas covered in this review: Based on the published literature and available abstracts, this review describes the development of a CD30-directed antibodydrug conjugate, brentuximab vedotin (SGN-35), the preclinical activity of this agent in models of HL and ALCL, as well as the results of initial clinical trials. What the reader will gain: This review discusses the utility of using CD30 to target delivery of an antimitotic agent, the safety and activity of this approach, as well as potential future prospects and challenges in integrating this therapy into current treatment combinations. Take home message: In reviewing the initial results with brentuximab vedotin in relapsed HL and ALCL, brentuximab vedotin appears to be well tolerated and to have promising activity in CD30+ lymphomas.

Original languageEnglish (US)
Pages (from-to)99-105
Number of pages7
JournalExpert Opinion on Investigational Drugs
Volume20
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Antimitotic Agents
Anaplastic Large-Cell Lymphoma
Lymphoma
Hodgkin Disease
Lymphoproliferative Disorders
Stem Cell Transplantation
Therapeutics
Histology
Clinical Trials
Safety
Drug Therapy
cAC10-vcMMAE

Keywords

  • anaplastic large cell lymphoma
  • brentuximab vedotin
  • CD30
  • Hodgkin's lymphoma

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Brentuximab vedotin : Delivering an antimitotic drug to activated lymphoma cells. / Ansell, Stephen Maxted.

In: Expert Opinion on Investigational Drugs, Vol. 20, No. 1, 01.2011, p. 99-105.

Research output: Contribution to journalArticle

@article{670e110c46334b7ca7c01e33fd03be21,
title = "Brentuximab vedotin: Delivering an antimitotic drug to activated lymphoma cells",
abstract = "Importance of the field: Patients with relapsed or refractory CD30-positive lymphoproliferative disorders such as Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) commonly have a poor prognosis. Patients with these histologies who subsequently progress after salvage chemotherapy and autologous stem cell transplantation (ASCT) have very limited treatment options and are in need of novel effective therapies. Areas covered in this review: Based on the published literature and available abstracts, this review describes the development of a CD30-directed antibodydrug conjugate, brentuximab vedotin (SGN-35), the preclinical activity of this agent in models of HL and ALCL, as well as the results of initial clinical trials. What the reader will gain: This review discusses the utility of using CD30 to target delivery of an antimitotic agent, the safety and activity of this approach, as well as potential future prospects and challenges in integrating this therapy into current treatment combinations. Take home message: In reviewing the initial results with brentuximab vedotin in relapsed HL and ALCL, brentuximab vedotin appears to be well tolerated and to have promising activity in CD30+ lymphomas.",
keywords = "anaplastic large cell lymphoma, brentuximab vedotin, CD30, Hodgkin's lymphoma",
author = "Ansell, {Stephen Maxted}",
year = "2011",
month = "1",
doi = "10.1517/13543784.2011.542147",
language = "English (US)",
volume = "20",
pages = "99--105",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Brentuximab vedotin

T2 - Delivering an antimitotic drug to activated lymphoma cells

AU - Ansell, Stephen Maxted

PY - 2011/1

Y1 - 2011/1

N2 - Importance of the field: Patients with relapsed or refractory CD30-positive lymphoproliferative disorders such as Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) commonly have a poor prognosis. Patients with these histologies who subsequently progress after salvage chemotherapy and autologous stem cell transplantation (ASCT) have very limited treatment options and are in need of novel effective therapies. Areas covered in this review: Based on the published literature and available abstracts, this review describes the development of a CD30-directed antibodydrug conjugate, brentuximab vedotin (SGN-35), the preclinical activity of this agent in models of HL and ALCL, as well as the results of initial clinical trials. What the reader will gain: This review discusses the utility of using CD30 to target delivery of an antimitotic agent, the safety and activity of this approach, as well as potential future prospects and challenges in integrating this therapy into current treatment combinations. Take home message: In reviewing the initial results with brentuximab vedotin in relapsed HL and ALCL, brentuximab vedotin appears to be well tolerated and to have promising activity in CD30+ lymphomas.

AB - Importance of the field: Patients with relapsed or refractory CD30-positive lymphoproliferative disorders such as Hodgkin's lymphoma (HL) and anaplastic large-cell lymphoma (ALCL) commonly have a poor prognosis. Patients with these histologies who subsequently progress after salvage chemotherapy and autologous stem cell transplantation (ASCT) have very limited treatment options and are in need of novel effective therapies. Areas covered in this review: Based on the published literature and available abstracts, this review describes the development of a CD30-directed antibodydrug conjugate, brentuximab vedotin (SGN-35), the preclinical activity of this agent in models of HL and ALCL, as well as the results of initial clinical trials. What the reader will gain: This review discusses the utility of using CD30 to target delivery of an antimitotic agent, the safety and activity of this approach, as well as potential future prospects and challenges in integrating this therapy into current treatment combinations. Take home message: In reviewing the initial results with brentuximab vedotin in relapsed HL and ALCL, brentuximab vedotin appears to be well tolerated and to have promising activity in CD30+ lymphomas.

KW - anaplastic large cell lymphoma

KW - brentuximab vedotin

KW - CD30

KW - Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=78650301478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650301478&partnerID=8YFLogxK

U2 - 10.1517/13543784.2011.542147

DO - 10.1517/13543784.2011.542147

M3 - Article

C2 - 21121873

AN - SCOPUS:78650301478

VL - 20

SP - 99

EP - 105

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 1

ER -